Thymosinalpha1 stimulates cell proliferation by activating ERK1/2, JNK, and increasing cytokine secretion in human pancreatic cancer cells.
Li. Min M; Feurino. Louis W LW; Li. Fei F; Wang. Hao H; Zhai. Qihui Q; Fisher. William E WE; Chen. Changyi C; Yao. Qizhi Q
Key Findings
- Pancreatic cancer cells have higher levels of thymosin‑alpha‑1 compared to normal pancreas cells
- Adding synthetic thymosin‑alpha‑1 makes these cancer cells proliferate and activates growth pathways (ERK1/2, JNK)
- Thymosin‑alpha‑1 also boosts secretion of cytokines like IL‑10, IL‑13, and IL‑17 in the cancer cells
Practical Outcomes
- For biohackers, this suggests caution: using thymosin‑alpha‑1 might be risky if you have or are prone to pancreatic cancer. It’s not a recommended supplement for longevity or performance until safety is proven, especially in people with cancer risk.
Summary
The study found that thymosin‑alpha‑1, a peptide sometimes used for immune support, actually makes pancreatic cancer cells grow faster and releases more inflammation‑related signals, meaning it could potentially worsen cancer rather than help health.
Abstract
In this study, we investigated the expression and function of thymosinalpha1 (Thyalpha1) in human pancreatic cancer. We found that human pancreatic cancer cell lines Panc-1, Panc03.27, ASPC-1, and PL45 cells significantly over-expressed the mRNA of Thyalpha1 as compared to the normal human pancreatic ductal epithelium (HPDE) cells.. Thyalpha1 mRNA and protein levels were also over-expressed in clinical pancreatic adenocarcinoma specimens. In addition, synthetic Thyalpha1 significantly promoted Panc-1 cell proliferation and increased phosphorylation of ERK1/2 and JNK. Furthermore, Thyalpha1 increased the secretion of multiple cytokines including IL-10, IL-13, and IL-17 in Panc-1 cells. Thus, Thyalpha1 may have a new role in pancreatic cancer pathogenesis.
Study Information
pubmed
2006
2006-07-07T00:00:00.000Z
10.1016/j.canlet.2006.05.019